Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 3(1)
Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07409922Phase 1Not Yet Recruiting

Study of Single and Multiple Ascending Doses of KR23343 in Healthy Adult Participants

Role: lead

NCT07345390Phase 2Not Yet Recruiting

Safety, Efficacy and Pharmacokinetic Characteristics of KR230109 Cream in Facial Acne Vulgaris

Role: lead

NCT07113392Phase 3Not Yet Recruiting

A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension

Role: lead

All 3 trials loaded